1
|
Seufert J, Krishnan N, Darmstadt GL, Wang G, Bärnighausen T, Geldsetzer P. Subnational estimates of vitamin A supplementation coverage in children: a geospatial analysis of 45 low- and middle-income countries. Public Health 2024; 228:194-199. [PMID: 38394746 DOI: 10.1016/j.puhe.2024.01.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 01/03/2024] [Accepted: 01/19/2024] [Indexed: 02/25/2024]
Abstract
OBJECTIVES Vitamin A supplementation (VAS) can protect children from the adverse health consequences of vitamin A deficiency. Granular data on VAS coverage can guide global and national efforts to achieve universal VAS coverage. To provide geographically precise targeting of VAS programs and to monitor progress in reducing geographic disparities, we aimed to create high-resolution (5 × 5 km2) maps of VAS coverage in children under 5 years across VAS priority countries. STUDY DESIGN We used cross-sectional data from the Demographic and Health Surveys (DHS) program. METHODS We used data from the DHS program for United Nations Children's Fund -designated VAS priority countries between 2000 and 2017 with data available from 2005 or later. The outcome variable was the proportion of children under 5 years who received a vitamin A dose in each sampled cluster. We applied a Bayesian geostatistical approach incorporating geographic, climatic, and nutritional covariates to estimate VAS coverage for each cell. We estimated and mapped absolute VAS coverage, Bayesian uncertainty intervals, and exceedance probabilities. RESULTS Our sample included countries from Latin America and the Caribbean, Asia, and Africa. Most countries had estimated VAS coverage levels <70%, and our exceedance probabilities indicated high certainty that our estimates fell below this threshold in most grid cells. International variations were most notable in the Latin America and the Caribbean region and Africa. Intranational variations were greatest in some South Asian and West and Central African countries. CONCLUSIONS These prevalence and exceedance maps, especially used with data on indicators of VAS need, could help to improve equity.
Collapse
Affiliation(s)
- J Seufert
- Department of Economics and Business, KU Leuven, Leuven, Belgium.
| | - N Krishnan
- Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, USA
| | - G L Darmstadt
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - G Wang
- Department of Biology, Stanford University, Stanford, CA, USA
| | - T Bärnighausen
- Heidelberg Institute of Global Health, Medical Faculty, Heidelberg University, Heidelberg, Germany; Africa Research Institute, Durban, South Africa; Harvard Center for Population and Development Studies, Harvard University, Cambridge, MA, USA
| | - P Geldsetzer
- Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub, San Francisco, CA, USA
| |
Collapse
|
2
|
Dierks C, Ruf J, Seufert J, Kreissl M, Klein C, Spitzweg C, Kroiss M, Thomusch O, Lorenz K, Zielke A, Miething C. 1646MO Phase II ATLEP trial: Final results for lenvatinib/pembrolizumab in metastasized anaplastic and poorly differentiated thyroid carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Davis T, Desouza C, Bain S, Gondolf T, Hansen T, Holst I, Rea R, Seufert J. 563 The Effect of Once-Weekly Semaglutide on MACE and Blood Pressure by Race and Ethnicity: SUSTAIN 6 Post Hoc Analysis. Heart Lung Circ 2020. [DOI: 10.1016/j.hlc.2020.09.570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Desouza C, Bain SC, Gondolf T, Hansen T, Holst I, Rea RR, Seufert J. P6271The effect of semaglutide once weekly on MACE and blood pressure by race and ethnicity: SUSTAIN 6 post hoc analysis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
In SUSTAIN 6, subcutaneous semaglutide once weekly added to standard of care significantly reduced major adverse cardiovascular events (MACE: non-fatal myocardial infarction, non-fatal stroke or death) vs placebo over 2 years in T2D subjects.
Purpose
Assess the effect of semaglutide vs placebo on MACE and blood pressure (BP) by race and ethnicity in a post hoc analysis of SUSTAIN 6.
Methods
Subjects were randomised to semaglutide 0.5 mg, 1.0 mg or volume-matched placebo. Data for the two semaglutide-dose groups were pooled and compared to the pooled placebo groups. Time-to-event data were analysed with a Cox proportional hazards model. Changes from baseline to week 104 were analysed using analysis of covariance. The interaction between treatment and subgroup was added to the models.
Results
Overall, 3,297 patients received treatment. Subgroups included Caucasian, Asian, Black/African American, Other (race), and Hispanic, non-Hispanic (ethnicity). Mean baseline characteristics were similar across subgroups (age 64.7 years, HbA1c 8.7%, diabetes duration 14.2 years). Time to composite MACE and individual components were improved with semaglutide across all subgroups. Semaglutide affected BP similarly across race and ethnicity, except for systolic BP in Black/African American subjects (Table).
Race Ethnicity Caucasian Asian Black/African American Other Interaction p-value Hispanic Non-Hispanic Interaction p-value Semaglutide (n) 1,384 121 108 35 256 1,392 Placebo (n) 1,352 152 113 32 254 1,395 MACE and individual outcomes MACE HR [95% CI] 0.76 [0.58; 1.00] 0.58 [0.25; 1.34] 0.72 [0.23; 2.28] 0.46 [0.08; 2.50] 0.8793 0.67 [0.33; 1.36] 0.74 [0.57; 0.96] 0.7978 CV death HR [95% CI] 0.98 [0.63; 1.50] 0.32 [0.04; 2.85] 1.01 [0.06; 16.20] n/a† 0.8089 0.79 [0.31; 2.00] 1.00 [0.63; 1.59] 0.6521 Non-fatal MI HR [95% CI] 0.69 [0.45; 1.07] 0.97 [0.36; 2.60] 1.37 [0.31; 6.12] 0.31 [0.03; 3.00] 0.6637 0.65 [0.18; 2.31] 0.74 [0.50; 1.10] 0.8562 Non-fatal stroke HR [95% CI] 0.70 [0.42; 1.16] 0.31 [0.04; 2.77] n/a‡ n/a‡ 0.9176 0.73 [0.16; 3.27] 0.60 [0.36; 0.99] 0.7995 Blood pressure at week 104 Systolic BP* ETD (mmHg) [95% CI] −1.92 [−3.09; −0.74] −4.98 [−8.61; 1.35] 4.47 [0.15; 8.79] −11.02 [−18.45; −3.60] 0.0008 −3.22 [−5.93; −0.51] −1.81 [−2.98; −0.64] 0.3489 Diastolic BP* ETD (mmHg) [95% CI] 0.36 [−0.32; 1.04] −1.31 [−3.43; 0.80] −0.07 [−2.56; 2.43] −3.41 [−7.73; 0.92] 0.1871 −0.18 [−1.75; 1.39] 0.16 [−0.52; 0.83] 0.6981 *Treatment difference between semaglutide and placebo (pooled 0.5 and 1.0 mg values for each treatment group) at week 104. †No events in the placebo group; ‡No events in the semaglutide group. BP, blood pressure; CI, confidence interval; ETD, estimated treatment difference; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction.
Conclusion
Overall there was no evidence of a differential effect of semaglutide on risk reduction in MACE and its components and on BP across race and ethnicity subgroups in this post hoc analysis.
Acknowledgement/Funding
Novo Nordisk A/S
Collapse
Affiliation(s)
- C Desouza
- University of Nebraska Medical Center, Omaha, United States of America
| | - S C Bain
- Swansea University, School of Medicine, Swansea, United Kingdom
| | | | - T Hansen
- Novo Nordisk A/S, Søborg, Denmark
| | - I Holst
- Novo Nordisk A/S, Søborg, Denmark
| | - R R Rea
- Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Brazil
| | - J Seufert
- University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany
| |
Collapse
|
5
|
Abstract
BACKGROUND Inhibitors of sodium-glucose cotransporters type 2 (SGLT-2) are a class of oral antidiabetic drugs with a novel specific mode of action in the kidneys. OBJECTIVE The effects of SGLT-2 inhibitors on cardiovascular (CV) and renal endpoints in outcome trials with type 2 diabetes patients. MATERIAL AND METHODS Differential analysis and interpretation of the results of outcome trials with the SGLT-2 inhibitors empagliflozin, canagliflozin and dapagliflozin in type 2 diabetes mellitus. RESULTS In the EMPA-REG OUTCOME trial, empagliflozin demonstrated a significant reduction in major cardiac adverse events (MACE), hospitalization for heart failure (HHI), renal endpoints, CV and total mortality vs. placebo in >7000 patients with type 2 diabetes and established CV disease over 3.1 years. In the CANVAS program, canagliflozin demonstrated a significant reduction of MACE, HHI and renal endpoints vs. placebo in >10,000 patients with type 2 diabetes and high CV risk over 2.4 years. In the CREDENCE trial, canagliflozin demonstrated a significant reduction of a combined renal endpoint and CV endpoints vs. placebo in >4000 patients with type 2 diabetes and established kidney disease with albuminuria over 2.6 years. In the DECLARE-TIMI 58 trial, dapagliflozin demonstrated a significant reduction in a combined endpoint of CV death and HHI vs. placebo in >17,000 patients with type 2 diabetes and established CV disease or with multiple CV risk factors over 3.1 years. CONCLUSION Outcome trials with SGLT-2 inhibitors have collectively demonstrated cardioprotective and nephroprotective effects in patients with type 2 diabetes and high CV risk. The use of SGLT-2 inhibitors is recommended in current guidelines and consensus statements as primary combination partners for metformin in patients with type 2 diabetes and established CV disease, high CV risk, heart failure or kidney disease.
Collapse
Affiliation(s)
- J Seufert
- Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Medizinische Fakultät, Universität Freiburg, Hugstetter Straße 55, 79106, Freiburg, Deutschland.
| | - K Laubner
- Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Medizinische Fakultät, Universität Freiburg, Hugstetter Straße 55, 79106, Freiburg, Deutschland.
| |
Collapse
|
6
|
Roider T, Frauhammer F, Seufert J, Bordas M, Stolarczyk M, Rabe S, Malm J, Bruch P, Hundemer M, Rippe K, Goeppert B, Seiffert M, Brors B, Mechtersheimer G, Müller-Tidow C, Fröhling S, Schlesner M, Huber W, Anders S, Dietrich S. TRANSCRIPTIONAL AND GENOMIC INTRA-TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.45_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- T. Roider
- Department of Medicine V; Hematology, Oncology and Rheumatology, University of Heidelberg; Heidelberg Germany
| | - F. Frauhammer
- Centre for Molecular Biology; University of Heidelberg; Heidelberg Germany
| | - J. Seufert
- Bioinformatics and Omics Data Analytics; German Cancer Research Center (DKFZ); Heidelberg Germany
| | - M. Bordas
- Department of Molecular Genetics; German Cancer Research Center (DKFZ); Heidelberg Germany
| | - M. Stolarczyk
- Department of Medicine V; Hematology, Oncology and Rheumatology, University of Heidelberg; Heidelberg Germany
| | - S. Rabe
- Department of Medicine V; Hematology, Oncology and Rheumatology, University of Heidelberg; Heidelberg Germany
| | - J. Malm
- Division of Chromatin Networks; German Cancer Research Center (DKFZ) and Bioquant; Heidelberg Germany
| | - P. Bruch
- Department of Medicine V; Hematology, Oncology and Rheumatology, University of Heidelberg; Heidelberg Germany
| | - M. Hundemer
- Department of Medicine V; Hematology, Oncology and Rheumatology, University of Heidelberg; Heidelberg Germany
| | - K. Rippe
- Division of Chromatin Networks; German Cancer Research Center (DKFZ) and Bioquant; Heidelberg Germany
| | - B. Goeppert
- Institute of Pathology; University of Heidelberg; Heidelberg Germany
| | - M. Seiffert
- Department of Molecular Genetics; German Cancer Research Center (DKFZ); Heidelberg Germany
| | - B. Brors
- Bioinformatics and Omics Data Analytics; German Cancer Research Center (DKFZ); Heidelberg Germany
| | - G. Mechtersheimer
- Institute of Pathology; University of Heidelberg; Heidelberg Germany
| | - C. Müller-Tidow
- Department of Medicine V; Hematology, Oncology and Rheumatology, University of Heidelberg; Heidelberg Germany
| | - S. Fröhling
- Translational Oncology; National Center for Tumor Diseases (NCT); Heidelberg Germany
| | - M. Schlesner
- Bioinformatics and Omics Data Analytics; German Cancer Research Center (DKFZ); Heidelberg Germany
| | - W. Huber
- Genome Biology; European Molecular Biology Laboratory (EMBL); Heidelberg Germany
| | - S. Anders
- Centre for Molecular Biology; University of Heidelberg; Heidelberg Germany
| | - S. Dietrich
- Department of Medicine V; Hematology, Oncology and Rheumatology, University of Heidelberg; Heidelberg Germany
| |
Collapse
|
7
|
Fritsche A, Anderten H, Pfohl M, Pscherer S, Borck A, Pegelow K, Bramlage P, Seufert J. HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs. BMJ Open Diabetes Res Care 2019; 7:e000668. [PMID: 31423316 PMCID: PMC6688703 DOI: 10.1136/bmjdrc-2019-000668] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2019] [Revised: 06/19/2019] [Accepted: 07/02/2019] [Indexed: 12/25/2022] Open
Abstract
OBJECTIVES To identify real-world, age-related trends in the use of insulin glargine 100 U/mL (Gla-100) as part of basal-supported oral therapy (BOT). RESEARCH DESIGN AND METHODS The prospective, observational Titration and Optimization registry enrolled patients with poorly controlled type 2 diabetes mellitus initiated on Gla-100 BOT. The primary outcome was the proportion of patients with capillary fasting blood glucose (FBG) ≤110 mg/dL on ≥2 occasions and/or who met their individual HbA1c target within 12 months. RESULTS 2462 patients were analyzed (<65 years: n=1122; 65-74 years: n=771; ≥75 years: n=569). Diabetes duration (6.8, 8.9, and 11.2 years, p<0.0001) and proportion of women (40.7%, 47.9%, and 55.7%, p<0.0001) increased with age. Baseline HbA1c was highest in <65-year-olds (8.6% vs 8.4% and 8.5%, p<0.0001). Gla-100 up-titration until 12 months was highest in <65-year-olds (+11.6 U/day), compared with 65-74 (+10.2 U/day) and ≥75 years (+8.8; p<0.0001) but similar by units per kilogram, as was the decrease in FBG (<65: -64.1 mg/dL; 65-74: -56.1 mg/dL; ≥75: -53.4 mg/dL) and HbA1c (<65: -1.47%; 65-74: -1.31%; ≥75: -1.22%, p<0.0001). At 12 months, 65.9% of participants met the primary endpoint, with no significant difference between age groups. The proportion achieving their individual HbA1c target was lower for <65-year-olds (46.0% vs 54.3% and 54.7%; p<0.02). Symptomatic hypoglycemia incidence was more common in the ≥75-year-old group (3.4% vs 1.4% and 1.4%; p=0.0126). CONCLUSIONS BOT with Gla-100 results in similar improvements of glycemic values with low risk of hypoglycemia across age groups. Given the link between HbA1c and long-term cardiovascular risk, ensuring appropriately stringent target-setting, intensification of basal insulin and making sure hypoglycemia is avoided is of paramount importance. TRIAL REGISTRATION NUMBER Database: https://awbdb.bfarm.de; Identifier: 1641; Date of registration: September 23, 2013.
Collapse
Affiliation(s)
| | - Helmut Anderten
- Gemeinschaftspraxis Anderten-Krok & Partner, Hildesheim, Germany
| | - Martin Pfohl
- Medizinische Klinik I, Evang. Krankenhaus Bethesda gGmbH, Duisburg, Germany
| | - Stefan Pscherer
- Klinik für Innere Medizin III, Sophien- undHufeland-Klinikum, Weimar, Germany
| | - Anja Borck
- Sanofi-Aventis Deutschland GmbH, Berlin, Germany
| | | | - Peter Bramlage
- Institut für Pharmakologie und Präventive Medizin, Cloppenburg, Germany
| | - J Seufert
- Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Medizinische Fakultät, Albert-Ludwig-Universität Freiburg, Freiburg, Germany
| |
Collapse
|
8
|
Bellary S, Jodar E, Seufert J, Damgaard L, Holst AG, Leiter L. Sustain 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.07.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Seufert J, Nauck M, Rosenstock J, Hansen T, Vrazic H, Vilsboll T. P2857Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2857] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J Seufert
- University of Freiburg, Faculty of Medicine, Freiburg, Germany
| | - M Nauck
- Ruhr University Bochum (RUB), St Josef Hospital, Bochum, Germany
| | - J Rosenstock
- Dallas Diabetes Research Center at Medical City, Dallas, United States of America
| | - T Hansen
- Novo Nordisk A/S, Søborg, Denmark
| | - H Vrazic
- Novo Nordisk A/S, Søborg, Denmark
| | - T Vilsboll
- Steno Diabetes Center Copenhagen, Copenhagen, Denmark
| |
Collapse
|
10
|
Liu F, Zhang W, Utech T, Ringwald M, Seufert J, Päth G. ETV5 knockdown enhances loss of streptozotocin- and palmitate-induced viability in pancreatic INS-1E beta cells. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1657799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- F Liu
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - W Zhang
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - T Utech
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - M Ringwald
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - J Seufert
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - G Päth
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| |
Collapse
|
11
|
Lanzinger S, Karges W, Raddatz D, Merger S, Seufert J, Thon A, Staab D, Laimer M, Holl R. Pankreopriver Diabetes mellitus: Gibt es Unterschiede in pathogenetischen Untergruppen? – Ergebnisse aus dem DPV-Register. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S Lanzinger
- Universität Ulm, Institut für Epidemiologie und medizinische Biometrie, ZIBMT, Ulm, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), München-Neuherberg, Germany
| | - W Karges
- Universitätsklinikum Aachen, Sektion Endokrinologie und Diabetologie – Medizinische Klinik III, RWTH Aachen, Germany
| | - D Raddatz
- Universitätsmedizin Göttingen, Klinik für Gastroenterologie und gastrointestinale Onkologie, Göttingen, Germany
| | - S Merger
- Klinikum Coburg, Klinik für Endokrinologie, Diabetologie, Stoffwechsel- und Ernährungsmedizin, Coburg, Germany
| | - J Seufert
- Universitätsklinikum und Medizinische Fakultät Freiburg, Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Freiburg, Germany
| | - A Thon
- Medizinische Hochschule Hannover, Klinik für Pädiatrische Pneumologie, Allergologie & Neonatologie, Hannover, Germany
| | - D Staab
- Charité – Universitätsmedizin Berlin, Klinik für Pädiatrie m. S. Pneumologie und Immunologie, Berlin, Germany
| | - M Laimer
- Universitätsspital Bern, Universitätsklinik für Diabetologie, Endokrinologie, Ernährungsmedizin & Metabolismus (UDEM), Bern, Switzerland
| | - R Holl
- Universität Ulm, Institut für Epidemiologie und medizinische Biometrie, ZIBMT, Ulm, Germany
- Deutsches Zentrum für Diabetesforschung (DZD), München-Neuherberg, Germany
| |
Collapse
|
12
|
Seufert J, Fritsche A, Pscherer S, Anderten H, Pegelow K, Pfohl M. Erfolg einer Umstellung auf Insulin glargin 300 E/ml (Gla-300) nach Versagen einer basalunterstützten oralen Therapie (BOT) bei Typ-2-Diabetespatienten – 6-Monats-Ergebnisse der TOP-2-Studie. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- J Seufert
- Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg, Germany
| | - A Fritsche
- Medizinische Klinik IV, Universitätsklinikum Tübingen, Tübingen, Germany
| | - S Pscherer
- Klinik für Innere Medizin III, Sophien- und Hufeland-Klinikum, Weimar, Germany
| | - H Anderten
- Gemeinschaftspraxis Dres. Anderten-Krok & Kollegen, Hildesheim, Germany
| | - K Pegelow
- Sanofi-Aventis Deutschland GmbH, Berlin, Germany
| | - M Pfohl
- Medizinische Klinik I, Evang. Bethesda-Krankenhaus, Duisburg, Germany
| |
Collapse
|
13
|
Jódar E, Seufert J, Damgaard LH, Holst AG, Leiter LA. SUSTAIN 6: Effekt von Semaglutid auf kardiovaskuläre Endpunkte im zeitlichen Verlauf bei Patienten mit Typ 2 Diabetes (Post-hoc Auswertung). DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- E Jódar
- Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid, Spain
| | - J Seufert
- Klinik für Innere Medizin II, Endokrinologie und Diabetologie, Freiburg, Germany
| | | | | | - LA Leiter
- Li Ka Shing Knowledge Institute and Keenan Research Centre for Biomedical Science, St. Michael's Hospital, University of Toronto, Toronto, Canada
| |
Collapse
|
14
|
Potasso L, Perakakis N, Lamprinou A, Arendt LC, Peter A, Rasenack R, Päth G, Seufert J, Laubner K. The T risk allele of TCF7L2 rs 7903146 is associated with impaired insulin secretion rather than insulin resistance: A clinical pilot study in women with a history of gestational diabetes (GDM). DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- L Potasso
- Uniklinik Freiburg, Innere II, Freiburg, Germany
| | - N Perakakis
- Uniklinik Freiburg, Innere II, Freiburg, Germany
| | - A Lamprinou
- University Hospital Tübingen, Tübingen, Germany
- Institut für Diabetes-Forschung und Metabolische Erkrankungen (IDM) – Metabolic Imaging des Helmholtz-Zentrums München an der Universität Tübingen, Tübingen, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - LC Arendt
- Uniklinik Freiburg, Innere II, Freiburg, Germany
| | - A Peter
- University Hospital Tübingen, Tübingen, Germany
- Institut für Diabetes-Forschung und Metabolische Erkrankungen (IDM) – Metabolic Imaging des Helmholtz-Zentrums München an der Universität Tübingen, Tübingen, Germany
- German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - R Rasenack
- Uniklinik Freiburg, Division of Perinatology, Freiburg, Germany
| | - G Päth
- Uniklinik Freiburg, Innere II, Freiburg, Germany
| | - J Seufert
- Uniklinik Freiburg, Innere II, Freiburg, Germany
| | - K Laubner
- Uniklinik Freiburg, Innere II, Freiburg, Germany
| |
Collapse
|
15
|
Fritsche A, Pscherer S, Pfohl M, Anderten H, Pegelow K, Seufert J. Umstellung des Basalinsulins auf Insulin glargin 300 E/ml (Gla-300) nach Versagen der Basis-Bolus-Therapie (ICT) mit einem anderen Basalinsulin verbesserte bei Typ-1-Diabetespatienten die Blutzucker-Einstellung – 6-Monats-Ergebnisse der Toujeo-Neo-T1DM-Studie. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- A Fritsche
- Medizinische Klinik IV, Universitätsklinikum Tübingen, Tübingen, Germany
| | - S Pscherer
- Klinik für Innere Medizin III, Sophien- und Hufeland-Klinikum, Weimar, Germany
| | - M Pfohl
- Medizinische Klinik I, Evang. Bethesda-Krankenhaus, Duisburg, Germany
| | - H Anderten
- Gemeinschaftspraxis Dres. Anderten-Krok & Kollegen, Hildesheim, Germany
| | - K Pegelow
- Sanofi-Aventis Deutschland GmbH, Berlin, Germany
| | - J Seufert
- Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg, Germany
| |
Collapse
|
16
|
Fonseca VF, Capehorn MC, Garg SG, Jódar E, Birch S, Holst AG, Seufert J. Die Abnahme der Insulinresistenz bei Patienten mit Typ 2 Diabetes durch Semaglutid ist primär durch die Gewichtsabnahme vermittelt (SUSTAIN 1 – 3). DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- VF Fonseca
- Tulane University Health Sciences Center, New Orleans, United States
| | - MC Capehorn
- Rotherham Insitute for Obesity, Roterham, United Kingdom
| | - SG Garg
- University of Colorado Denver, Denver, CO, United States
| | - E Jódar
- Hospital Universitario Quirón Salud Madrid, Facultad de Ciencias de la Salud, Universidad Europea de Madrid, Madrid, Spain
| | - S Birch
- Novo Nordisk, Søborg, Denmark
| | | | - J Seufert
- Klinik für Innere Medizin II, Endokrinologie und Diabetologie, Freiburg, Germany
| |
Collapse
|
17
|
Pfohl M, Pscherer S, Fritsche A, Anderten H, Pegelow K, Seufert J. Wirksamkeit von Insulin glargin 300 E/ml (Gla-300) bei Neueinstellung von Typ-2-Diabetespatienten auf eine basalunterstützte orale Therapie (BOT) nach Versagen der oralen Antidiabetika- (OAD-)Therapie – 6-Monats-Ergebnisse der Toujeo-1-Studie. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M Pfohl
- Medizinische Klinik I, Evang. Bethesda-Krankenhaus, Duisburg, Germany
| | - S Pscherer
- Klinik für Innere Medizin III, Sophien- und Hufeland-Klinikum, Weimar, Germany
| | - A Fritsche
- Medizinische Klinik IV, Universitätsklinikum Tübingen, Tübingen, Germany
| | - H Anderten
- Gemeinschaftspraxis Dres. Anderten-Krok & Kollegen, Hildesheim, Germany
| | - K Pegelow
- Sanofi-Aventis Deutschland GmbH, Berlin, Germany
| | - J Seufert
- Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg, Germany
| |
Collapse
|
18
|
Zhang W, Liu F, Seufert J, Päth G. Mesenchymal stem cells (MSC) reduce necrosis and apoptosis of pancreatic INS-1E beta cells during alloxan and streptozotocin exposure. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- W Zhang
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - F Liu
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - J Seufert
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - G Päth
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| |
Collapse
|
19
|
Hartmann B, Bohn B, Danne T, Bramlage P, Grünerbel A, Illig G, Femerling M, Kress S, Seufert J, Holl RW. Charakteristika von Patienten mit Typ 1 und Typ 2 Diabetes mellitus im Verlauf der Markteinführung von Insulin Glargin U300. Eine Analyse von 5676 Patienten unter Insulin Glargin U300 Therapie aus den Diabetesregistern DPV und DIVE. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- B Hartmann
- Klinikum Ludwigshafen, Medizinische Klinik C, Ludwigshafen, Germany
| | - B Bohn
- Universität Ulm, Institut für Epidemiologie und Medizinische Biometrie, Ulm, Germany
- Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Germany
| | - T Danne
- Kinder- und Jugendkrankenhaus „AUF DER BULT“, Hannover, Germany
| | - P Bramlage
- Institut für Pharmakologie und Präventive Medizin, Mahlow, Germany
| | - A Grünerbel
- Diabeteszentrum München-Süd, München, Germany
| | - G Illig
- Kliniken Südostbayern AG- Kreisklinik Bad Reichenhall, Bad Reichenhall, Germany
| | | | - S Kress
- Vinzentius-Krankenhaus Landau, Landau, Germany
| | - J Seufert
- Universitätsklinikum Freiburg, Medizinische Fakultät, Freiburg, Germany
| | - RW Holl
- Universität Ulm, Institut für Epidemiologie und Medizinische Biometrie, Ulm, Germany
- Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Germany
| |
Collapse
|
20
|
Pscherer S, Pfohl M, Fritsche A, Anderten H, Pegelow K, Seufert J. Umstellung des Basalinsulins auf Insulin glargin 300 E/ml (Gla-300) nach Versagen einer Basis-Bolus- (ICT) oder einer basalunterstützten oralen Therapie mit einmal täglich prandialem Insulin (BOTplus) mit einem anderen Basalinsulin verbesserte bei Typ-2-Diabetespatienten die glykämische Kontrolle – 6-Monats-Ergebnisse der Toujeo-Neo-T2DM-Studie. DIABETOL STOFFWECHS 2018. [DOI: 10.1055/s-0038-1641911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- S Pscherer
- Klinik für Innere Medizin III, Sophien- und Hufeland-Klinikum, Weimar, Germany
| | - M Pfohl
- Medizinische Klinik I, Evang. Bethesda-Krankenhaus, Duisburg, Germany
| | - A Fritsche
- Medizinische Klinik IV, Universitätsklinikum Tübingen, Tübingen, Germany
| | - H Anderten
- Gemeinschaftspraxis Dres. Anderten-Krok & Kollegen, Hildesheim, Germany
| | - K Pegelow
- Sanofi-Aventis Deutschland GmbH, Berlin, Germany
| | - J Seufert
- Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Freiburg, Germany
| |
Collapse
|
21
|
Jodar E, Seufert J, Damgaard L, Holst A, Leiter L. 3910SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.3910] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Fritsche A, Anderten H, Borck A, Pegelow K, Pfohl M, Pscherer S, Seufert J. Patienten mit unzureichend kontrolliertem Typ-2 Diabetes mellitus unter oralen Antidiabetika: Einfluss des Alters auf die Insulin Glargin U100-Titration in der hausärztlichen Praxis. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- A Fritsche
- Universitätsklinik Tübingen, Medizinische Klinik IV, Tübingen, Germany
| | - H Anderten
- Gemeinschaftspraxis Anderten-Krok & Partner, Hildesheim, Germany
| | - A Borck
- Sanofi Aventis Deutschland GmbH, Berlin, Germany
| | - K Pegelow
- Sanofi Aventis Deutschland GmbH, Berlin, Germany
| | - M Pfohl
- Evangelisches Krankenhaus Bethesda, Duisburg, Germany
| | - S Pscherer
- Sophien- und Hufeland-Klinikum, Weimar, Germany
| | - J Seufert
- Universitätsklinikum Freiburg, Freiburg, Germany
| |
Collapse
|
23
|
Riedel N, Laubner K, Lautenbach A, Gijbels P, Stengel R, Eberl T, Dederichs F, Aberle J, Seufert J. Efficacy and safety development and nutritive changes during one-year treatment with the duodenal-jejunal bypass liner (DJBL). DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- N Riedel
- Department for Endocrinology and Diabetology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - K Laubner
- Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Medical Faculty, Freiburg, Germany
| | - A Lautenbach
- Department for Endocrinology and Diabetology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - P Gijbels
- Obesity Centre Düsseldorf, St. Martinus-Krankenhaus, Düsseldorf, Germany
| | - R Stengel
- Diakonissenanstalt Emmaus, Niesky, Germany
| | - T Eberl
- Donau-Ries-Klinik, Department of Internal Medicine/Gastroenterology, Donauwörth, Germany
| | - F Dederichs
- Department of Internal Medicine/Gastroenterology, Gelsenkirchen, Germany
| | - J Aberle
- Department for Endocrinology and Diabetology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
| | - J Seufert
- Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Medical Faculty, Freiburg, Germany
| |
Collapse
|
24
|
Rosenbauer J, Stahl-Pehe A, Neu A, Rothe U, Reuter HM, Siegel E, Badenhoop K, Seufert J, Holl RW. Prävalenz des Typ-1-Diabetes bei Erwachsenen in Deutschland – Schätzung auf der Basis von bundesweitem DPV-Register und NRW-Diabetesregister. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- J Rosenbauer
- Deutsches Diabetes-Zentrum, Leibniz-Institut an der Heinrich-Heine-Universität Düsseldorf, Institut für Biometrie und Epidemiologie, Düsseldorf, Germany
| | - A Stahl-Pehe
- Deutsches Diabetes-Zentrum, Leibniz-Institut an der Heinrich-Heine-Universität Düsseldorf, Institut für Biometrie und Epidemiologie, Düsseldorf, Germany
| | - A Neu
- Universitäts-Klinikum Tübingen, Klinik für Kinder- und Jugendmedizin, Tübingen, Germany
| | - U Rothe
- Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Gesundheitswissenschaften/Public Health, Dresden, Germany
| | - HM Reuter
- Ambulantes Medizinisches Zentrum Jena, Diabetologische Schwerpunktpraxis, Jena, Germany
| | - E Siegel
- St. Josefkrankenhaus Heidelberg, Innere Medizin – Gastroenterologie, Diabetologie und Ernährungsmedizin, Heidelberg, Germany
| | - K Badenhoop
- Universitätsklinikum der Goethe-Universität Frankfurt, Medizinische Klinik 1 – SP Diabetologie und Endokrinologie, Frankfurt, Germany
| | - J Seufert
- Universitätsklinikum Freiburg, Klinik für Innere Medizin II – Abteilung Endokrinologie und Diabetologie, Freiburg, Germany
| | - RW Holl
- Deutsches Zentrum für Diabetesforschung (DZD), München-Neuherberg, Germany
| |
Collapse
|
25
|
Jabbour S, Seufert J, Scheen A, Karup C, Langkilde A. Sicherheit und Verträglichkeit von Dapagliflozin: Update für Frakturen, renale Sicherheit und diabetische Ketoazidosen. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- S Jabbour
- Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, United States
| | - J Seufert
- Universität Freiburg, Freiburg, Germany
| | - A Scheen
- University of Liège, Liege, Belgium
| | - C Karup
- AstraZeneca, Göteborg, Sweden
| | | |
Collapse
|
26
|
Seufert J, Anderten H, Borck A, Fritsche A, Pegelow K, Pscherer S, Pfohl M. Titration von Insulin Glargin U100 bei Patienten mit Typ-2 Diabetes und bislang unzureichender Blutzuckerkontrolle mit oralen Antidiabetika. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- J Seufert
- Universitätsklinikum Freiburg, Freiburg, Germany
| | - H Anderten
- Gemeinschaftspraxis Anderten-Krok & Partner, Hildesheim, Germany
| | - A Borck
- Sanofi Aventis Deutschland GmbH, Berlin, Germany
| | | | - K Pegelow
- Sanofi Aventis Deutschland GmbH, Berlin, Germany
| | - S Pscherer
- Sophien- und Hufeland-Klinikum, Weimar, Germany
| | - M Pfohl
- Evangelisches Krankenhaus Bethesda, Duisburg, Germany
| |
Collapse
|
27
|
Seufert J, Lanzinger S, Schmid S, Karges W, Bergis D, Kerner W, Hummel M, Zimny S, Mader JK, Rosenbauer J, Holl RW. Epidemiologie diabetischer Ketoazidosen im Verlauf des Typ-1-Diabetes bei Erwachsenen: Daten der DPV-Initiative bei 45.764 Patienten. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- J Seufert
- Universitätsklinikum Freiburg, Klinik für Innere Medizin II, Abteilung Endokrinologie und Diabetologie, Freiburg, Germany
| | - S Lanzinger
- Universität Ulm, Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Ulm, Germany
| | - S Schmid
- Universitätsklinikum Schleswig-Holstein – Campus Lübeck, Medizinische Klinik 1 – Endokrinologie, Diabetologie, Internistische Adipositasmedizin, Lübeck, Germany
| | - W Karges
- Universitätsklinikum Aachen, Medizinische Klinik III, Sektion Endokrinologie und Diabetologie, Aachen, Germany
| | - D Bergis
- Universitätsklinikum Frankfurt, Medizinische Klinik 1, Schwerpunkt Endokrinologie und Diabetologie, Frankfurt, Germany
| | - W Kerner
- Klinikum Karlsburg der Klinikgruppe Dr. Guth GmbH & Co. KG, Klinik für Diabetes & Stoffwechselkrankheiten, Karlsburg, Germany
| | - M Hummel
- Diabetes Schwerpunktpraxis, Rosenheim, Germany
| | - S Zimny
- HELIOS Kliniken Schwerin GmbH, Klinik für Allgemeine Innere Medizin, Endokrinologie und Diabetologie, Diabeteszentrum, Schwerin, Germany
| | - JK Mader
- Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Endokrinologie und Diabetologie, Graz, Austria
| | - J Rosenbauer
- Deutsches Zentrum für Diabetesforschung (DZD), München-Neuherberg, Germany
| | - RW Holl
- Universität Ulm, Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Ulm, Germany
| |
Collapse
|
28
|
Zhang W, Liu C, Peradze N, Straetener J, Laubner K, Perakakis N, Seufert J, Päth G. Mesenchymal Stem Cell (MSC)-derived humoral factors promote survival of insulin producing pancreatic β-cells during intrinsic cellular stress via Akt and ERK1/2 signalling. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- W Zhang
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - C Liu
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - N Peradze
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - J Straetener
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - K Laubner
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - N Perakakis
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - J Seufert
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| | - G Päth
- Uniklinik Freiburg, Innere Medizin II, Endokrinologie & Diabetologie, Freiburg, Germany
| |
Collapse
|
29
|
Peradze N, Straetener J, Zhang W, Liu F, Laubner K, Perakakis N, Seufert J, Päth G. Exocrine AR42J acinar cells enhance viability of cocultured endocrine INS-1E beta cells. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- N Peradze
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| | - J Straetener
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| | - W Zhang
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| | - F Liu
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| | - K Laubner
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| | - N Perakakis
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| | - J Seufert
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| | - G Päth
- Universitätsklinikum Freiburg, Innere Medizin II, Freiburg, Germany
| |
Collapse
|
30
|
Mielenz J, Hansel E, Seufert J, Laubner K. Erhöhte Prävalenz depressiver Symptomatik bei Frauen mit Gestationsdiabetes. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- J Mielenz
- Universitätsklinikum Freiburg, Klinik für Innere Medizin II, Endokrinologie und Diabetologie, Freiburg, Germany
| | - E Hansel
- Universitätsklinikum Freiburg, Klinik für Innere Medizin II, Endokrinologie und Diabetologie, Freiburg, Germany
| | - J Seufert
- Universitätsklinikum Freiburg, Klinik für Innere Medizin II, Endokrinologie und Diabetologie, Freiburg, Germany
| | - K Laubner
- Universitätsklinikum Freiburg, Klinik für Innere Medizin II, Endokrinologie und Diabetologie, Freiburg, Germany
| |
Collapse
|
31
|
Bramlage P, Lanzinger S, Danne T, Hummel M, Kaltheuner M, Raddatz D, Rathmann W, Reuter HM, Seufert J, Holl RW. Regionale Unterschiede in der Therapie des Typ-2-Diabetes mellitus (T2DM) und der diabetologischen Ergebnisqualität in Deutschland – eine Analyse der Diabetesregister DPV und DIVE. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- P Bramlage
- Institut für Pharmakologie und Präventive Medizin, Mahlow, Germany
| | - S Lanzinger
- Universität Ulm, Institut für Epidemiologie und medizinische Biometrie, ZIBMT, Ulm, Germany
| | - T Danne
- Kinder-und Jugendkrankenhaus „Auf der Bult“, Hannover, Germany
| | - M Hummel
- Helmholtz Diabetes Center, München, Germany
| | - M Kaltheuner
- Gemeinschaftspraxis Kaltheuner Boxberg, Leverkusen, Germany
| | - D Raddatz
- Universitätsmedizin Göttingen, Klinik für Gastroenterologie und gastrointestinale Onkologie, Bereich Endokrinologie, Göttingen, Germany
| | - W Rathmann
- Deutsches Diabetes-Zentrum, Leibniz-Institut an der Heinrich-Heine-Universität Düsseldorf, Institut für Biometrie und Epidemiologie, Düsseldorf, Germany
| | - HM Reuter
- Diabetologische Gemeinschaftspraxis Reuter, Reuter-Ehrlich, Schramm, Jena, Germany
| | - J Seufert
- Universitätsklinikum Freiburg, Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Freiburg, Germany
| | - RW Holl
- Universität Ulm, Institut für Epidemiologie und medizinische Biometrie, ZIBMT, Ulm, Germany
| |
Collapse
|
32
|
Röhlen N, Hilger H, Seufert J, Laubner K. 17q12 Recurrent Deletion Syndrome – a rare cause for diabetes mellitus type MODY5. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- N Röhlen
- Uniklinik Freiburg, Medizinische Klinik II, Freiburg, Germany
| | - H Hilger
- Uniklinik Freiburg, Medizinische Klinik II, Freiburg, Germany
| | - J Seufert
- Uniklinik Freiburg, Medizinische Klinik II, Freiburg, Germany
| | - K Laubner
- Uniklinik Freiburg, Medizinische Klinik II, Freiburg, Germany
| |
Collapse
|
33
|
Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, Alba M. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab 2016; 18:812-9. [PMID: 27160639 PMCID: PMC5089595 DOI: 10.1111/dom.12684] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Revised: 04/11/2016] [Accepted: 05/01/2016] [Indexed: 01/14/2023]
Abstract
AIMS To evaluate the efficacy and safety of titrated canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sitagliptin. METHODS In this randomized, double-blind study, patients with T2DM (N = 218) on metformin ≥1500 mg/day and sitagliptin 100 mg received canagliflozin 100 mg or placebo. After 6 weeks, the canagliflozin dose was increased from 100 to 300 mg (or from placebo to matching placebo) if all of the following criteria were met: baseline estimated glomerular filtration rate ≥70 ml/min/1.73 m(2) ; fasting self-monitored blood glucose ≥5.6 mmol/l (≥100 mg/dl); and no volume depletion-related adverse events (AEs) within 2 weeks before dose increase. Endpoints included change in glycated haemoglobin (HbA1c) at week 26 (primary); proportion of patients achieving HbA1c <7.0%; and changes in fasting plasma glucose (FPG), body weight and systolic blood pressure (SBP). Safety was assessed using AE reports. RESULTS Overall, 85.4% of patients were titrated to canagliflozin 300 mg or matching placebo (mean ± standard deviation time to titration 6.2 ± 0.8 weeks). At week 26, canagliflozin (pooled 100 and 300 mg) demonstrated superiority in HbA1c reduction versus placebo (-0.91% vs. -0.01%; p < 0.001). Canagliflozin provided significant reductions in FPG, body weight and SBP compared with placebo (p < 0.001). The overall AE incidence was 39.8 and 44.4% for canagliflozin and placebo, respectively. Canagliflozin was associated with an increased incidence of genital mycotic infections. CONCLUSIONS Titrated canagliflozin significantly improved HbA1c, FPG, body weight and SBP, and was generally well tolerated over 26 weeks in patients with T2DM as add-on to metformin and sitagliptin.
Collapse
Affiliation(s)
- H W Rodbard
- Endocrine and Metabolic Consultants, Rockville, MD, USA
| | - J Seufert
- Department of Endocrinology and Diabetology, Clinic for Internal Medicine II, University Medical Center, Freiburg, Germany
| | - N Aggarwal
- Aggarwal and Associates Ltd, Brampton, ON, Canada
| | - A Cao
- Janssen Research & Development, LLC, Raritan, NJ, USA
| | - A Fung
- Janssen Research & Development, LLC, Raritan, NJ, USA
| | - M Pfeifer
- Janssen Scientific Affairs, LLC, Raritan, NJ, USA
| | - M Alba
- Janssen Research & Development, LLC, Raritan, NJ, USA
| |
Collapse
|
34
|
Vora J, Seufert J, Solberg H, Kinduryte O, Johansen T, Hollander P. Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials. Diabetes Obes Metab 2016; 18:716-20. [PMID: 26663320 PMCID: PMC5067686 DOI: 10.1111/dom.12621] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2015] [Revised: 11/18/2015] [Accepted: 11/30/2015] [Indexed: 11/29/2022]
Abstract
We examined insulin antibody formation in patients with type 1 (T1D) or type 2 diabetes (T2D) treated with once-daily insulin degludec (IDeg) or insulin glargine (IGlar) to evaluate the impact of antibody formation on efficacy and safety. Insulin antibodies were measured using subtraction radioimmunoassays in six phase IIIa clinical trials using IDeg (n = 2250) and IGlar (n = 1184). Spearman's correlation coefficient was used to evaluate associations between cross-reacting antibodies and change from baseline glycated haemoglobin (HbA1c) and insulin dose. IDeg- and IGlar-specific antibodies remained low [<1% bound/total radioactivity (B/T)] and with low levels of antibodies cross-reacting with human insulin in patients with T1D (<20% B/T) and T2D (<6% B/T). Spearman's correlation coefficients between insulin antibody levels and change in HbA1c or insulin dose were low in both treatment groups. No clinically meaningful differences in adverse event (AE) rates were observed in patients with >10% B/T or without an absolute increase in antibodies cross-reacting with human insulin. IDeg treatment resulted in few immunogenic responses in patients with T1D and T2D; antibody formation was not associated with change in HbA1c, insulin dose or rates of AEs.
Collapse
Affiliation(s)
- J. Vora
- Department of Diabetes and EndocrinologyRoyal Liverpool University HospitalsLiverpoolUK
| | - J. Seufert
- Division of Endocrinology and Diabetology, Department of Internal Medicine IIUniversity Hospital of FreiburgFreiburgGermany
| | | | | | | | | |
Collapse
|
35
|
Seufert J, Bailey T, Barkholt Christensen S, Nauck MA. Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta-analysis of seven phase III trials. Diabetes Obes Metab 2016; 18:721-4. [PMID: 26679282 PMCID: PMC5324626 DOI: 10.1111/dom.12623] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 10/08/2015] [Accepted: 12/14/2015] [Indexed: 12/20/2022]
Abstract
This meta-analysis of seven randomized, placebo-controlled studies (total 3222 patients) evaluated whether type 2 diabetes (T2D) duration affects the changes in blood glucose control and body weight that can be achieved with liraglutide and placebo. With liraglutide 1.2 mg, shorter diabetes duration was associated with a significantly greater, but clinically non-relevant, difference in glycated haemoglobin (HbA1c) reduction (p < 0.05), i.e. a 0.18% (1.96 mmol/mol) reduction in HbA1c per 10 years shorter diabetes duration. With liraglutide 1.8 mg, shorter diabetes duration was associated with a small but statistically significant trend for greater fasting plasma glucose (FPG) reduction (p < 0.05), i.e. a 0.38 mmol/l reduction in FPG per 10 years shorter diabetes duration. Neither the liraglutide 1.8 mg nor placebo results showed a significant association between HbA1c and diabetes duration and neither the liraglutide 1.2 mg nor placebo results showed a significant association between FPG and diabetes duration. Likewise, neither liraglutide nor placebo showed a significant association between change in weight and diabetes duration. These results suggest diabetes duration has a clinically negligible effect on achievable blood glucose control and weight outcomes with liraglutide and placebo in patients with T2D.
Collapse
Affiliation(s)
- J Seufert
- Division of Endocrinology and Diabetology Department of Internal Medicine II, University Hospital of Freiburg, Freiburg, Germany
| | - T Bailey
- AMCR Institute Inc, Escondido, CA, USA
| | | | - M A Nauck
- Division of Diabetology Medical Department, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany
| |
Collapse
|
36
|
Seufert J, Pscherer S, Fritsche A, Anderten H, Pegelow K, Pfohl M. Titrations- und Optimierungsstudie (TOP) für die Initiierung von Insulin glargin 100 E/ml (Gla-100) bei Typ-2-Diabetespatienten mit unzureichender Blutzuckereinstellung unter oralen Antidiabetika – Baseline-Daten. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
37
|
Singler E, Siegmund T, Päth G, Hruby B, Tränkle S, Straetener J, Hille M, Kriedemann D, Seufert J, Laubner K. Insulinabgabegenauigkeiten von Patch-Pumpen versus Schlauchpumpen – Eine systematische Analyse unter Laborbedingungen. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
38
|
Zhang W, Peradze N, Liu F, Straetener J, Laubner K, Perakakis N, Seufert J, Päth G. Mesenchymal stem cell (MSC)-mediated activation of ERK1/2 signaling does not contribute to maintained survival of cocultured alloxan-treated INS-1E beta cells. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Nicolaus L, Bettinger D, Neumann-Haefelin C, Perakakis N, Thimme R, Schwacha H, Seufert J, Laubner K. Verbesserung der Nicht-alkoholischen Fettlebererkrankung (NAFLD) durch Implantation eines endoskopischen duodenalen Bypasses (EndoBarrier®) bei Patienten mit Typ 2 Diabetes (T2Dm) und Übergewicht. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
Seufert J, Pscherer S, Anderten H, Pegelow K, Pfohl M. Titrations- und Optimierungsstudie 2 (TOP-2) zur Untersuchung der Effizienz einer Umstellung auf Insulin glargin 300 E/ml (Gla-300) bei Typ-2-Diabetespatienten mit basalunterstützter oraler Therapie und inadäquater glykämischer Kontrolle – Baseline-Daten. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
41
|
Fritsche A, Pfohl M, Pscherer S, Anderten H, Pegelow K, Seufert J. Titrations- und Optimierungsstudie (TOP) für die Initiierung von Insulin glargin 100 E/ml (Gla-100) bei Typ-2-Diabetespatienten mit unzureichender Blutzuckereinstellung- 6-Monats-Ergebnisse. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
42
|
Pscherer S, Pfohl M, Anderten H, Pegelow K, Seufert J. Nicht-interventionelle Studie zur Untersuchung der Effizienz des Wechsels der Basalinsulinkomponente bei einer BOTplus oder intensivierten Insulintherapie (ICT) zu Insulin glargin 300 E/ml bei Typ-1- und Typ-2-Diabetespatienten mit inadäquater glykämischer Kontrolle. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
43
|
Seufert J. „Das gab es noch nie“ – Hohe Auszeichnungen für deutsche Diabetes-Forscher. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1566960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
44
|
Päth G, Seufert J. Stammzelltherapie des Diabetes mellitus Typ 1. Diabetologe 2015. [DOI: 10.1007/s11428-015-0024-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Schütt M, Zimmermann A, Hood R, Hummel M, Seufert J, Siegel E, Tytko A, Holl RW. Gender-specific Effects of Treatment with Lifestyle, Metformin or Sulfonylurea on Glycemic Control and Body Weight: A German Multicenter Analysis on 9 108 Patients. Exp Clin Endocrinol Diabetes 2015; 123:622-6. [PMID: 26285070 DOI: 10.1055/s-0035-1559608] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Effects of diabetes treatment are strongly connected to individual factors, but the relevant role of gender has not been addressed so far. This observational study evaluates whether monotherapy with lifestyle, metformin or sulfonylurea has gender-specific effects on glycemic control and/or body weight. Data of 9 108 patients with type 2 diabetes from 129 German diabetes centers were assessed by a standardized, prospective, computer-based diabetes care and outcome documentation system (DPV-Wiss-database; age 63.1±12.8 years, diabetes duration 5.7±7.4 years, HbA1c 55±17.7 mmol/mol [7.2±1.6%], BMI 30.6±6.1 kg/m(2), 49.3% female patients). Antidiabetic concepts included lifestyle intervention (n=5,787), metformin (n=2,180), sulfonylurea (n=943) or other antidiabetic drugs (n=198), respectively. HbA1c and body weight were compared before and after a stable monotherapeutical period of 0.8±0.4 years. Women had a significantly higher reduction of body weight after treatment with lifestyle (women-0.8±0.1 vs. men-0.2±0.1 kg; p<0.05), metformin (women-1.8±0.2 vs. men-1.2±0.2 kg; p<0.05) or sulfonylurea drugs (women-0.9±0.2 vs. men - 0.1±0.2 kg; p<0.05), whereas men displayed significantly higher HbA1c-reductions after treatment with lifestyle (women-6.9±0.2 mmol/mol [- 0.6±0.02%] vs. men-7.5±0.2 mmol/mol [0.7±0.02%]; p<0.05) and metformin only (women-6.3±0.3 mmol/mol [- 0.6±0.03%] vs. men - 7.4±0.3 mmol/mol [- 0.7±0.03%]; p<0.05). No differences were seen for sulfonylurea monotherapy concerning the HbA1c-reduction (women - 5.6±0.5 mmol/mol [- 0.5±0.05%] vs. men-6.4±0.4 mmol/mol [- 0.6±0.04%]; p=0.196). In summary, antidiabetic treatment concepts might result in gender-specific effects on body weight and HbA1c. Gender might therefore represent another important factor in the context of an individualized treatment management of type 2 diabetes.
Collapse
Affiliation(s)
- M Schütt
- Department of Internal Medicine I, University of Lübeck, Germany
| | - A Zimmermann
- Diabetes-Schwerpunktpraxis, Bad Aibling, Germany
| | - R Hood
- Helios Klinikum Duisburg, Germany
| | - M Hummel
- Diabetes-Schwerpunktpraxis Rosenheim & Institute of Diabetes Research, Helmholtz Zentrum München, Germany
| | - J Seufert
- Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Germany
| | - E Siegel
- St. Josefs Hospital Heidelberg, Department of Internal Medicine, Germany
| | - A Tytko
- St. Vincenz Hospital, Department of Internal Medicine, Limburg, Germany
| | - R W Holl
- Institute of Epidemiology and medical Biometry, University of Ulm, Ulm, Germany
| | | | | |
Collapse
|
46
|
Seufert J. GLP-1-Rezeptoragonisten in der Therapie des Typ-2-Diabetes. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1553166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
47
|
Mehana AE, Straetener J, Baumann J, Perakakis N, Laubner K, Seufert J, Päth G. Preserved insulin response of Nupr1-transgenic islets during diabetogenic injury is correlated with reduced secretion of IL-1beta and enhanced secretion of IL-1 receptor antagonist. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
48
|
Perakakis N, Arend L, Potasso L, Lamprinou A, Polyzou E, Kassanos A, Rasenack R, Päth G, Seufert J, Laubner K. Effects of the gestational diabetes-risk polymorphism rs10501320 of MADD gene on metabolic phenotype and glucose homeostasis in women with history of gestational diabetes. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
49
|
Bohn B, Kerner W, Seufert J, Kempe HP, Jehle P, Best F, Füchtenbusch M, Knauerhase A, Zeitoun M, Hofer M, Holl RW. Trend in der antihyperglykämischen Therapieform bei Patienten mit Typ 1 und Typ 2 Diabetes in den Jahren 2000 bis 2014: Real-Life Daten aus dem DPV-Register. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
50
|
Laubner K, Scheuing N, Bauer M, Konrad K, Lilienthal E, Lorenzen N, Poeplau T, Teeken A, Thon A, Seufert J, Holl RW, Schebek M. Association of CFTR mutations with Cystic Fibrosis related Diabetes (CFRD) in Germany and Austria: a multicentre analysis from the DPV registry. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|